Revvity Inc
RVTY: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$616.00 | Bgwxxxl | Lcbzdmf |
Revvity Earnings: 2023 Outlook Cut Mildly on Life Sciences Uncertainty, China Diagnostics Weakness
Narrow-moat Revvity (formerly known as PerkinElmer) reported weak first-quarter results that were about as expected but trimmed its guidance for the full year, which appears to be pushing down shares in early trading. At first glance, our bottom-line assumptions remain within management's new guidance range, and we do not anticipate changing our $162 fair value estimate based on this announcement. The shares still appear moderately undervalued to us.